Literature DB >> 25856547

Activation of the γ-Aminobutyric Acid Type B (GABA(B)) Receptor by Agonists and Positive Allosteric Modulators.

Katie M Brown1, Kuldeep K Roy2, Gregory H Hockerman1, Robert J Doerksen2, David A Colby2.   

Abstract

Since the discovery of the GABA(B) agonist and muscle relaxant baclofen, there have been substantial advancements in the development of compounds that activate the GABA(B) receptor as agonists or positive allosteric modulators. For the agonists, most of the existing structure-activity data apply to understanding the role of substituents on the backbone of GABA as well as replacing the carboxylic acid and amine groups. In the cases of the positive allosteric modulators, the allosteric binding site(s) and structure-activity relationships are less well-defined; however, multiple classes of molecules have been discovered. The recent report of the X-ray structure of the GABA(B) receptor with bound agonists and antagonists provides new insights for the development of compounds that bind the orthosteric site of this receptor. From a therapeutic perspective, these data have enabled efforts in drug discovery in areas of addiction-related behavior, the treatment of anxiety, and the control of muscle contractility.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25856547     DOI: 10.1021/jm5018913

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Agonists of the γ-aminobutyric acid type B (GABAB) receptor derived from β-hydroxy and β-amino difluoromethyl ketones.

Authors:  Munia F Sowaileh; Amy E Salyer; Kuldeep K Roy; Jinu P John; James R Woods; Robert J Doerksen; Gregory H Hockerman; David A Colby
Journal:  Bioorg Med Chem Lett       Date:  2018-04-07       Impact factor: 2.823

2.  Therapeutic Advantage of the Positive Allosteric Modulators of the GABA-B Receptor.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2017-04-12       Impact factor: 4.345

3.  Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment.

Authors:  Mehdi Farokhnia; Mikela B Sheskier; Mary R Lee; April N Le; Erick Singley; Sofia Bouhlal; Timmy Ton; Zhen Zhao; Lorenzo Leggio
Journal:  Neuropharmacology       Date:  2018-04-14       Impact factor: 5.250

4.  Ligand-guided homology modelling of the GABAB2 subunit of the GABAB receptor.

Authors:  Thibaud Freyd; Dawid Warszycki; Stefan Mordalski; Andrzej J Bojarski; Ingebrigt Sylte; Mari Gabrielsen
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 5.  The GABAB Receptor-Structure, Ligand Binding and Drug Development.

Authors:  Linn Samira Mari Evenseth; Mari Gabrielsen; Ingebrigt Sylte
Journal:  Molecules       Date:  2020-07-07       Impact factor: 4.411

6.  QSAR and Molecular Docking Studies of the Inhibitory Activity of Novel Heterocyclic GABA Analogues over GABA-AT.

Authors:  Josué Rodríguez-Lozada; Erika Tovar-Gudiño; Juan Alberto Guevara-Salazar; Rodrigo Said Razo-Hernández; Ángel Santiago; Nina Pastor; Mario Fernández-Zertuche
Journal:  Molecules       Date:  2018-11-15       Impact factor: 4.411

7.  Natural Product Isoliquiritigenin Activates GABAB Receptors to Decrease Voltage-Gate Ca2+ Channels and Glutamate Release in Rat Cerebrocortical Nerve Terminals.

Authors:  Tzu-Yu Lin; Cheng-Wei Lu; Pei-Wen Hsieh; Kuan-Ming Chiu; Ming-Yi Lee; Su-Jane Wang
Journal:  Biomolecules       Date:  2021-10-18

8.  Novel-Substituted Heterocyclic GABA Analogues. Enzymatic Activity against the GABA-AT Enzyme from Pseudomonas fluorescens and In Silico Molecular Modeling.

Authors:  Erika Tovar-Gudiño; Juan Alberto Guevara-Salazar; José Raúl Bahena-Herrera; José Guadalupe Trujillo-Ferrara; Zuleyma Martínez-Campos; Rodrigo Said Razo-Hernández; Ángel Santiago; Nina Pastor; Mario Fernández-Zertuche
Journal:  Molecules       Date:  2018-05-09       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.